VOGX logo

Vogenx Inc.

VOGX
Healthcare|Biotechnology|US
$17.45
-0.78 (-4.28%)
Next Earnings Report
Feb 5, 2027
EPS est. -$0.25
Financing Filings (last 12 months)
4
Shelf registrations / offering prospectuses — latest Aug 12, 2026 (424B4). Possible dilution.

Upcoming Data Readouts (1)

Oct 2027
Est. completion
P2Postbariatric Hypoglycemia
Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia
NCT07760961n=36

Recent Press Releases

Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia
Oct 15, 2026 · Accesswire
Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer
Oct 9, 2026 · Accesswire
Vogenx Appoints Ken Toombs to Board of Directors
Sep 22, 2026 · Accesswire
Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering
Aug 17, 2026 · PRNewsWire
Vogenx Announces Closing of Initial Public Offering
Aug 13, 2026 · Accesswire
Vogenx Announces Pricing of Initial Public Offering
Aug 11, 2026 · Accesswire

SEC Filings (20)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 6, 202610-QQuarterly reportDocumentIndex
Nov 6, 20268-KMaterial eventDocumentIndex
Oct 9, 20268-KMaterial eventDocumentIndex
Sep 22, 20268-KMaterial eventDocumentIndex
Sep 17, 202610-QQuarterly reportDocumentIndex
Sep 8, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 19, 20268-KMaterial eventDocumentIndex
Aug 13, 20268-KMaterial eventDocumentIndex
Aug 13, 2026S-8Employee stock planDocumentIndex
Aug 12, 2026424B4Offering prospectusDocumentIndex
Aug 11, 2026EFFECTDocumentIndex
Aug 11, 2026CERTDocumentIndex
Aug 10, 20268-A12BDocumentIndex
Aug 10, 2026S-1/AIPO / offering registrationDocumentIndex
Jul 29, 2026S-1/AIPO / offering registrationDocumentIndex
Jul 15, 2026S-1IPO / offering registrationDocumentIndex
Jun 30, 2026DRS/ADocumentIndex
Apr 2, 2026DRS/ADocumentIndex
Feb 20, 2026DRSDocumentIndex
Jan 7, 2026DDocumentIndex